Tesamorelin
PeptideThe medical score (82) exceeds the community score (68) because clinical trials [s6, s7, s14] demonstrate clear effects in a defined patient population (HIV lipodystrophy), whereas community users cite the rebound effect upon discontinuation [s8] and high costs as primary criticisms [c1, c4, c5].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Tesamorelin is the only GHRH analogue with a genuine FDA approval (HIV-associated lipodystrophy) and solid RCT evidence for visceral fat reduction — which clearly sets it apart from most peptides in the biohacking space. In the EU it has no approval; acquiring or using it without a prescription in Germany is illegal under the AMG. The biggest practical drawback is that the effect is not durable — visceral fat returns after discontinuation, which raises a serious cost-benefit question at up to $1,500/month. It is contraindicated in active malignancies and requires careful monitoring in anyone with glucose dysregulation or diabetes.
Description
Synthetic GHRH analogue, FDA-approved for reduction of abdominal fat in HIV-associated lipodystrophy; not approved in the EU [s1, s2].
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), consisting of 44 amino acids and stabilized against native GHRH by conjugation with trans-3-hexenoic acid [s5]. It was originally developed by Theratechnologies and received FDA approval in 2010 under the trade name Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [s1]. In two pivotal Phase III trials (LIPO-010 and CTR-1011), tesamorelin (2 mg/day subcutaneously) reduced visceral adipose tissue (VAT) by approximately 15–20% versus placebo after 26 weeks [s6, s7]. The effect persists only as long as treatment is continued; visceral fat returns upon discontinuation [s8, s9]. Beyond the lipodystrophy indication, tesamorelin is being investigated in clinical studies for additional applications: reduction of liver fat (NAFLD/NASH) [s10], cognitive function in older adults with and without mild cognitive impairment (MCI) [s11], as well as visceral adiposity in non-HIV patients and use as a supplement to exercise [s12]. In the EU, the marketing authorisation application (MAA) was withdrawn by Ferrer Internacional, meaning tesamorelin is not authorised as a medicinal product in Germany or other EU countries [s2]. Procurement via the grey market (research chemical suppliers) is legally problematic under German law [s3, s4].
Legal Status (DE)
In the United States, tesamorelin (Egrifta) has been approved as a prescription medication since 2010 (FDA indication: HIV-associated lipodystrophy) [s1]. In the EU, the marketing authorisation application was withdrawn from the EMA [s2]; tesamorelin therefore holds no medicinal product authorisation in Germany, Austria, or Switzerland. Under the German Medicinal Products Act (AMG), it is classified as an unauthorised medicinal product; acquisition, possession, and use without a medical prescription are not legal. The designation "Research Chemical" does not provide protection under the AMG or the Anti-Doping Act (AntiDopG) [s3, s4].
Mechanism of Action
Tesamorelin binds with high affinity to GHRH receptors on somatotroph cells in the anterior pituitary [s5, s13]. Receptor activation triggers a cAMP/PKA signalling cascade that stimulates both the synthesis and secretion of growth hormone (GH) [s13]. The released GH acts on peripheral cells, including hepatocytes, where it stimulates the production of insulin-like growth factor 1 (IGF-1) [s5]. IGF-1 mediates many of the anabolic and lipolytic effects of GH: it activates hormone-sensitive lipase in visceral adipose tissue, promotes lipolysis, and thereby selectively reduces visceral fat [s1, s6]. In contrast to exogenous recombinant growth hormone (rhGH), tesamorelin stimulates endogenous GH pulsatility, producing more physiological GH/IGF-1 levels without supraphysiological excess [s5]. The effect does not persist after discontinuation, as no endogenous correction of GHRH deficiency occurs [s8]. At the neuronal level, evidence suggests that elevated GH/IGF-1 levels can increase cerebral GABA concentrations and reduce an Alzheimer-associated metabolite, which may explain the cognitive improvements observed in pilot data [s11].
Dosing
HIV-assoziierte Lipodystrophie (FDA-zugelassen)
- Dose
- 2 mg (Egrifta) or 1.28 mg (Egrifta WR) daily
- Frequency
- 1× täglich
- Route
- injektion-subkutan
- Duration
- 26 Wochen (Studienendpunkt); Langzeitanwendung möglich bei anhaltendem Nutzen
- Timing
- In the evening before bedtime (physiological GH pulse alignment)
- With food
- vermeiden
Kognitive Funktion (Forschungsprotokoll, Off-Label)
- Dose
- 1 mg daily
- Frequency
- 1× täglich
- Route
- injektion-subkutan
- Duration
- 20 Wochen
- Timing
- 30 minutes before bedtime
- With food
- vermeiden
Viszerale Adipositas / Off-Label (Biohacking-Kontext)
- Dose
- 1–2 mg daily
- Frequency
- 1× täglich
- Route
- injektion-subkutan
- Duration
- 10–12 Wochen (Community-Protokoll, nicht FDA-validiert)
- Timing
- In the evening
- With food
- vermeiden
FDA-approved maximum dose: 2 mg/day (Egrifta) or 1.28 mg/day (Egrifta WR) [s1, s16]. Dose reduction or discontinuation is recommended in cases of persistently elevated IGF-1 levels (>3 SDS) [s16].
Tesamorelin must be administered by subcutaneous injection; oral or other routes of administration are not effective. The solution should be used immediately after reconstitution and must not be frozen [s16]. In Germany, use outside of a medically supervised therapy is legally problematic [s3, s4].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Reaktionen an der Injektionsstelle (Erythem, Pruritus, Schwellung, Schmerz) Most frequently reported adverse effect in Phase III trials; documented in 34% of patients at 52 weeks [s16]. | häufig | leicht |
| Arthralgien (Gelenkschmerzen) GH-induced fluid retention and tissue changes can cause joint complaints; documented in clinical trials [s8, s17]. | häufig | leicht |
| Myalgien (Muskelschmerzen) und Parästhesien GH elevation can lead to tissue fluid retention, resulting in tingling and muscle pain [s17]. | häufig | leicht |
| Periphere Ödeme (Flüssigkeitsretention) GH-induced sodium retention can lead to edema; generally mild and reversible [s16, s15]. | gelegentlich | leicht |
| Glukoseintoleranz / Verschlechterung einer bestehenden Diabeteserkrankung GH elevation may reduce insulin sensitivity. The FDA recommends considering discontinuation of tesamorelin upon onset or worsening of glucose intolerance [s16, s18]. | gelegentlich | moderat |
| Hypersensitivitätsreaktionen (Urtikaria, Flush, Dyspnoe) Rare anaphylactoid reactions are described in the prescribing information; immediate discontinuation upon occurrence [s16]. | selten | schwer |
| Stimulation von malignem Tumorwachstum (theoretisch) IGF-1 elevation may promote growth of pre-existing malignant tumors. In Phase III studies, one basal cell carcinoma occurred in each group; no causal relationship established [s5, s17]. | theoretisch | schwer |
| Rebound-Effekt (Rückkehr der viszeralen Adipositas nach Absetzen) After discontinuation of tesamorelin, visceral adipose tissue returns within weeks to months; no lasting effect documented [s8, s9]. | häufig | moderat |
Contraindications
IGF-1 elevation may promote growth of malignant tumors; tesamorelin is contraindicated in active malignancies [s16, s5].
Fetal safety not investigated; tesamorelin is contraindicated in pregnancy [s16].
Known hypersensitivity is an absolute contraindication [s16].
GH effects are altered in uncontrolled hormonal disorders; correction of these conditions is required prior to initiation of therapy [s16].
GH elevation may impair glycemic control; close blood glucose monitoring is necessary in diabetic patients [s16, s18].
Tesamorelin is not approved for children and adolescents; growth plates may close prematurely due to GH stimulation [s16].
Interactions
Synergistic
Combinations of GHRH analogues with GHRPs can produce synergistic GH release through distinct receptor mechanisms (mechanistically plausible, insufficient clinical evidence) [s13].
Hexarelin acts as a GHRP and activates the GHS-R1a receptor, while tesamorelin stimulates the GHRH receptor. Simultaneous activation of both receptor pathways produces synergistic GH release exceeding the additive effect of either peptide alone.
CJC-1295 is also a GHRH analogue and can enhance GH secretion in combination with ipamorelin. However, combination with tesamorelin offers limited additional benefit, as both utilize the same GHRH receptor pathway.
CJC-1295 (Mod GRF 1-29) shares the GHRH receptor pathway with tesamorelin. In combination with a GHRP such as ipamorelin, both GHRH analogs can increase GH pulsatility, though combining two GHRH analogs produces less synergism than a GHRH+GHRP combination.
Tesamorelin and BPC-157 are frequently combined for tissue regeneration and recovery. Based on mechanistic data, BPC-157 upregulates GH receptor expression, which may potentiate the effects of tesamorelin-induced GH.
GHK-Cu is used in combination with tesamorelin for cutaneous and metabolic synergies. Both substances can act complementarily on tissue repair and collagen synthesis without exhibiting antagonistic interactions.
Ipamorelin activates the GHS-R1a receptor (ghrelin receptor), while tesamorelin stimulates the GHRH receptor. Simultaneous activation of both receptor pathways produces synergistic GH release exceeding the additive effects of each peptide. This GHRH+GHRP combination is considered one of the best-documented synergies in peptide therapy.
GHRP-2, as a potent GHS-R1a agonist, stimulates GH release via a complementary receptor pathway to tesamorelin. Combining a GHRH analog with a GHRP such as GHRP-2 produces synergistic GH pulses exceeding the individual effects.
GHRP-6 acts as a GHS-R1a agonist and synergistically complements tesamorelin's GHRH receptor stimulation. This GHRH+GHRP combination maximizes GH pulsatility by activating both axes of pituitary GH regulation.
TB-500 is used in combination with tesamorelin for tissue regeneration and recovery. Both substances act complementarily on tissue repair, with TB-500 promoting cell migration and angiogenesis while tesamorelin mediates anabolic effects via GH/IGF-1.
Caution
Glucocorticoids may attenuate the GH-stimulating effect of tesamorelin; efficacy may be reduced with concomitant use [s17].
Tesamorelin may reduce insulin sensitivity; dose adjustment of antidiabetic agents may be required [s16, s18].
Interactions with certain ARV medications may affect the metabolism of tesamorelin; clinically relevant interactions are not fully characterized [s17].
GH elevation may affect peripheral T4/T3 metabolism; thyroid function should be monitored during tesamorelin therapy [s16].
Tesamorelin may moderately reduce insulin sensitivity, while berberine exerts blood glucose-lowering effects. The combination may destabilize blood glucose and requires close monitoring of glucose levels.
Combining two GHRH analogs (tesamorelin and sermorelin) offers no clinically relevant added benefit and may lead to excessive GH and IGF-1 elevation, with increased risk of insulin resistance and joint complaints.
Tesamorelin may moderately reduce insulin sensitivity and mildly elevate blood glucose, while metformin acts as an insulin sensitizer with blood glucose-lowering effects. The combination may destabilize glucose metabolism and requires regular monitoring of blood glucose levels and HbA1c.
Community Evidence
Top reported benefits
- Noticeable reduction in visceral fat after 8–12 weeks
- Improved body composition and muscle tone
- Better post-workout recovery
- Clearly established evidence base as a deciding factor for tesamorelin (vs. CJC-1295)
Top reported issues
- Rebound effect after discontinuation (VAT return)
- High cost (approx. 500–1500 USD/month in the US)
- Injection burden (daily subcutaneous)
- Unclear legal status in Germany/EU
- No sustained fat loss without continuation of treatment
Several community users emphasise that the effect persists only as long as tesamorelin is taken [c1, c2]. German bodybuilding forums rate the benefit as low relative to the effort involved [c5]. No community consensus on off-label doses beyond the FDA protocol. Few reports of glucose issues in healthy individuals; however, explicit warnings are noted for diabetics [c3, c4].
Scientific Sources
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Badran AS, et al. (2026). Obesity Research & Clinical PracticeADOI - Clinical Review Report: Tesamorelin (Egrifta)
Canadian Agency for Drugs and Technologies in Health (CADTH) (2016). ALink - Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
Baker LD, Barsness SM, Borber S, et al. (2012). Archives of NeurologyBPMID:22869065 - Tesamorelin - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
National Institute of Diabetes and Digestive and Kidney Diseases (2020). NCBI Bookshelf / NIHBPMID:31643905 - Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial
Stanley TL, Falutz J, Marsolais C, et al. (2014). JAMAAPMID:24549548DOI - Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
Baker LD, Barsness SM, Borson S, et al. (2012). Archives of NeurologyAPMID:22869065DOI - NCT06554717 - Tesamorelin as an Adjunct to Exercise
ClinicalTrials.gov (2024). ClinicalTrials.govBLink - What is the mechanism of Tesamorelin Acetate?
Patsnap Synapse Editorial (2023). Patsnap SynapseCLink - Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Authors not fully available in search results, et al. (2026). ScienceDirect / ElsevierADOI - Can Tesamorelin cause long-term problems
Peptides Lab UK Editorial (2024). Peptides Lab UKCLink - EGRIFTA WR (tesamorelin for injection) Full Prescribing Information
Theratechnologies Inc. (2025). FDA / accessdata.fda.govALink - Tesamorelin - an overview
ScienceDirect Topics Editorial (2023). ScienceDirect TopicsBLink - Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
Falutz J, Potvin D, Mamputu JC, et al. (2017). PMC / Open AccessAPMID:28617892DOI - Tesamorelin: Was es wirklich kann – Wirkung, Vorteile, Studien & Sicherheit
Clinicx.ch Redaktion (2024). Clinicx.chCLink - Ferrer Internacional withdraws Egrifta MAA in Europe
Clinical Trials Arena Editorial (2013). Clinical Trials ArenaBLink - Tesamorelin
LiverTox (NIH/NCBI Bookshelf — curated monograph) (2018). LiverTox — Clinical and Research Information on Drug-Induced Liver InjuryBLink - Metabolic actions of growth hormone in normal adults and patients with type 2 diabetes and obesity (representative GHRH/GH/IGF-1 mechanism review — see notes)
Clemmons DR (2024). BLink - Peptide, Abnehmspritzen & Co.: Grauzone oder Strafbarkeit?
Anwalt.de Redaktion (2024). anwalt.de RechtstippsBLink - Peptide legal in Deutschland? Rechtslage 2026 – Peptide Culture
Peptide Culture Redaktion (2026). Peptide CultureCLink - Tesamorelin: A Clinical Research Overview of the GHRH Analogue
ClinicalPub Editorial (2024). ClinicalPubBLink - Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
Falutz J, Allas S, Blot K, et al. (2007). New England Journal of MedicineAPMID:17978289DOI - Results - Clinical Review Report: Tesamorelin (Egrifta) - NCBI Bookshelf
Canadian Drug Review (CADTH) (2019). NCBI Bookshelf / CADTHALink - HIV und more: Tesamorelin Meldungen 2010
hivandmore.de Redaktion (2010). hivandmore.deCLink - Efficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitors
Srinivasa S, Grinspoon SK, Bhatt DL, et al. (2024). PMC / Open AccessAPMID:39216956
Community Sources
Storage
Unopened
Store in refrigerator (2–8 °C), protected from light; do not freeze.
Opened
Use reconstituted solution immediately; do not freeze; do not shake.
Notes
Tesamorelin powder for injection must be reconstituted with the supplied solvent. After dissolution, the solution should be clear and colourless before use; turbid or discoloured solutions must be discarded [s16].